Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?

Jordi Remon; Lizza Hendriks; Sandrine Aspeslagh; Benjamin Besse

doi:10.1016/j.jtho.2019.07.004

Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?

Jordi Remon, Lizza Hendriks, Sandrine Aspeslagh, Benjamin Besse^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

106 Downloads (Pure)

Original language	English
Pages (from-to)	1701-1703
Number of pages	3
Journal	Journal of Thoracic Oncology
Volume	14
Issue number	10
DOIs	https://doi.org/10.1016/j.jtho.2019.07.004
Publication status	Published - Oct 2019

Keywords

LUNG-CANCER
EFFICACY
SAFETY

Access to Document

10.1016/j.jtho.2019.07.004Licence: Free access - publisher

Full TextFinal published version, 169 KBLicence: Taverne

Cite this

@article{c70b45efc2f04664b09b09f84f24ea0c,

title = "Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?",

keywords = "LUNG-CANCER, EFFICACY, SAFETY",

author = "Jordi Remon and Lizza Hendriks and Sandrine Aspeslagh and Benjamin Besse",

note = "Funding Information: Disclosures: Dr. Remon has received personal fees from OSE Immunotherapeutics; and has received other support from MSD, Boehringer, Pfizer , OSE Immunotherapeutics, Bristol-Myers Squibb , AstraZeneca , and Roche . Dr. Aspeslagh has received speaker fees from Roche, Amgen, AstraZeneca, Merck, Novartis, and Bristol-Myers Squibb. Dr. Besse reports grants from Abbvie, grants from Amgen, grants from AstraZeneca, grants from Biogen, grants from Blueprint Medicines, grants from BMS, grants from Celg{\`e}ne, grants from Eli-Lilly, grants from GSK, grants from Ignyta, grants from IPSEN, grants from Merck KGaA, grants from MSD, grants from Nektar, grants from Onxeo, grants from Pfizer, grants from Pharma Mar, grants from Sanofi, grants from Spectrum Pharmaceuticals, grants from Takeda, grants from Tiziana Pharma, outside the submitted work. The remaining author declares no conflict of interest. Funding Information: Disclosures: Dr. Remon has received personal fees from OSE Immunotherapeutics; and has received other support from MSD, Boehringer, Pfizer, OSE Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, and Roche. Dr. Aspeslagh has received speaker fees from Roche, Amgen, AstraZeneca, Merck, Novartis, and Bristol-Myers Squibb. Dr. Besse reports grants from Abbvie, grants from Amgen, grants from AstraZeneca, grants from Biogen, grants from Blueprint Medicines, grants from BMS, grants from Celg{\`e}ne, grants from Eli-Lilly, grants from GSK, grants from Ignyta, grants from IPSEN, grants from Merck KGaA, grants from MSD, grants from Nektar, grants from Onxeo, grants from Pfizer, grants from Pharma Mar, grants from Sanofi, grants from Spectrum Pharmaceuticals, grants from Takeda, grants from Tiziana Pharma, outside the submitted work. The remaining author declares no conflict of interest.",

year = "2019",

month = oct,

doi = "10.1016/j.jtho.2019.07.004",

language = "English",

volume = "14",

pages = "1701--1703",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",